Cytek Biosciences, Inc. (CTKB)
Nasdaq · Healthcare · Medical Devices
$6.09+3.75%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $792M
- Forward P/E
- 87.0
- 52-week range
- $3.31 – $6.18
- 52-week change
- +54.88%
- EPS (trailing)
- −$0.64
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $201M (+0.52%)
- Net income
- −$66.5M
- Operating margin
- −20.0%
- Free cash flow
- −$8.8M
From the company’s annual report on SEC EDGAR.
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
Headquarters: Fremont, United States · 682 employees · cytekbio.com